Hedge Fund News: Crispin Odey, Peter Kolchinsky & T Boone Pickens
Some of Europe's most powerful hedge fund managers are sharply divided on the outlook for English soccer club Manchester United PLC (NYSE:MANU) -0.17%, whose share price has ...
Posts Tagged ‘Hedge Fund:307’
Hedge Fund Highlights: Ken Griffin, Paul Tudor Jones & Bill Ackman
Citadel Investment Group founder Kenneth Griffin yesterday urged Congress not to ban high-frequency trading, but to focus on regulations that would improve market stability.
RA Capital Management Sells 800,000 Shares of Achillion Pharmaceuticals Inc. (ACHN)
RA Capital Management, managed by Peter Kolchinsky, has sold 800,000 shares of Achillion Pharmaceuticals Inc.
RA Capital Reports New 5.8% Position In Recently Public Versartis Inc (VSAR)
Peter Kolchinsky’s RA Capital Management has initiated a new position in Versartis Inc (NASDAQ:VSAR).
Ra Capital Management Reveals New Stake in Enanta Pharmaceuticals Inc (ENTA)
Peter Kolchinsky's Ra Capital Management disclosed a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
RA Capital Management Discloses New Stake in SANUWAVE Health Inc. (SNWV); Boosts Position in pSivida Corp. (PSDV)
In two recent filings with the U.S. Securities and Exchange Commission, Peter Kolchinsky’s RA Capital Management has revealed a new position in SANUWAVE Health Inc.
RA Capital Discloses New Passive Stake in Repros Therapeutics Inc (RPRX)
RA Capital Management, managed by Peter Kolchinsky, has revealed a new position in Repros Therapeutics Inc (NASDAQ:RPRX).
Ra Capital Management Revealed Stake in Dicerna Pharmaceuticals Inc (DRNA) After Deerfield and Brookside
Ra Capital Management, a fund managed by Peter Kolchinsky, disclosed, in a new filing with the Securities and Exchange Commission, that it owns 2.43 million shares of Dicerna ...
Ra Capital Management Initiates Stake in Furiex Pharmaceuticals Inc (FURX) After the Stock Jumped
Peter Kolchinsky's Ra Capital Management, has just disclosed initiating a 7.2% stake in Furiex Pharmaceuticals Inc (NASDAQ:FURX).
Hedge Fund News: Jamie Zimmerman, Perry Capital & Paul Singer
Women hedge fund managers have outperformed their male rivals, on average, for the second year in a row, according to professional services firm Rothstein Kass which tracks the...
Ra Capital Management Lowers Stake in Derma Sciences Inc (DSCI)
Peter Kolchinsky's Ra Capital Management has recently sold a total of 300,000 shares of Derma Sciences Inc (NASDAQ:DSCI).
Peter Kolchinsky, Ra Capital Management Inrease Stake in Achillion Pharmaceuticals Again
Peter Kolchinsky's hedge fund, Ra Capital Management disclosed upping its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) some more.
Peter Kolchinsky, Ra Capital Buy More Achillion Pharmaceuticals at $2.48/Share
Peter Kolchinsky's, RA Capital Management solidified its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) even more today.
Peter Kolchinsky’s RA Capital Has Been Very Active This Month
Since the beginning of November, Peter Kolchinsky's RA Capital Management has informed the U.S.
This Week’s 6 Most Important Hedge Fund Moves
As we approach the nexus of third quarter 13F filings (next week), hedge funds have been very active in 13D and 13G land.
Ra Capital Boosts Exposure in Dynavax to 9.9%
Peter Kolchinsky's Ra Capital Management surged its position in Dynavax Technologies Corporation (NASDAQ:DVAX) to almost 26 million shares, a new filing with the SEC has revealed...
Peter Kolchinsky, RA Capital Up Stake in Achillion Pharmaceuticals Even Higher
Peter Kolchinsky, Achillion Pharmaceuticals: This afternoon, Peter Kolchinsky and his hedge fund, RA Capital Management, strengthened their position in Achillion Pharmaceuticals...
Outerwall, Pandora & Achillion All Targets of Mega-Hedge Funds
Outerwall, Pandora, Achillion, hedge funds: It’s no secret that at Insider Monkey, we track hedge funds (discover why here).
Hedge Fund Week in Review: Activist Action
Here are the eleven most important moves made in the hedge fund world this week.
Bill Ackman reduced his Herbalife short significantly, replacing it with long-term put options.
Dan Loeb ups his activist campaign at Sotheby’s, snatching 9.
Peter Kolchinsky’s Biotech Fund Doubles Achillion Pharmaceuticals Position
RA Capital, Achillion Pharmaceuticals: In a 13G filing with the SEC, Peter Kolchinsky's RA Capital disclosed that it owns nearly 15% of infectious disease-focused biopharma player...
